Aims: EA-230 is a newly developed synthetic linear tetrapeptide (AQGV) derived from the chorionic gonadotropin hormone (β-hCG). We investigated the pharmacokinetics, safety and tolerability of EA-230 in healthy subjects using different administration strategies.
| INTRODUCTION
Systemic inflammation plays a detrimental role in various autoimmune diseases, but also during critical illness, such as sepsis, trauma and major surgery. In the latter group, an injurious systemic inflammatory response to a variety of inflammatory stimuli may occur, often resulting in pronounced tissue damage with associated organ failure and mortality rates up to 30%. [1] [2] [3] Despite its tremendous impact, current intensive care consists of supportive treatment, as no pharmaceutical interventions have proven effective in regulating the systemic inflammatory response to prevent organ injury. [4] [5] [6] Therefore, new therapeutic strategies are warranted.
The adaptation of the maternal immune system during pregnancy has provided a basis for research into new immunomodulatory strategies. Pregnancy represents a unique immunologic situation in which the maternal immune system tolerates the semi-allogeneic fetus, while maintaining pathogen clearing capacity. [7] [8] [9] This immune-tolerant antiinflammatory phenotype is also exemplified by the fact that various autoimmune diseases like rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriasis show attenuated disease activity during pregnancy and often relapse following delivery. [10] [11] [12] [13] [14] The hormonal milieu, in particular the release of human chorionic gonadotropin (hCG), is thought to play a pivotal role. 15 Produced throughout pregnancy, hCG is already present at a very early stage and has been shown to exert immunomodulatory effects. [16] [17] [18] [19] In addition to the integral hCG molecule, nicked fragments originating from the β-loop of hCG, which are abundantly present in the circulation during pregnancy, exert immunological effects. 20 Recent studies in animal models of systemic inflammation have shown that these oligopeptides exert immunomodulatory effects and limit organ failure and mortality. [21] [22] [23] [24] [25] [26] [27] [28] [29] Of particular interest is the linear tetrapeptide alanine-glutamine-glycine-valine (AQGV), which has shown the most promising effects up till now. This peptide preserved kidney function and substantially reduced mortality in murine models of renal ischaemia and reperfusion. 22 Furthermore, it attenuated the release of inflammatory mediators during haemorrhagic and endotoxemiainduced shock in mice and monkeys.
23, 24, 28 AQGV is currently developed under the product name EA-230 as a potential novel immune modulatory compound. The present work describes three phase I studies in which the first-in-human pharmacokinetics, safety and tolerability of EA-230 are investigated, using escalating single and multiple dosages as well as escalating continuous dosages.
| METHODS

| General
Double-blind, randomized, placebo-controlled, phase I studies in healthy subjects were conducted to evaluate pharmacokinetics, safety 
| Study medication
EA-230 and placebo were supplied as solution for injection in identical sterile single-use vials. EA-230 vials contained 11 ml of 40 mg/ml (single and multiple dosage studies) or 5 ml of 300 mg/ml (continuous dosage study) active substrate, and placebo vials contained an equivalent osmolar dose of sodium chloride solution. Vials were manufactured by Octoplus and HAL allergy BV, and quality controlled by PROXY Laboratories BV (both based in Leiden, The Netherlands).
Manufacturing, packaging, quality control and preparation were described in an Investigational Medicinal Product Dossier (IMPD) and complied with Good Manufacturing Practice (GMP) requirements.
Randomization, using a pre-determined randomization list, and preparation of study medication were performed by independent
What is already known about this subject
• Systemic inflammation can result in pronounced tissue damage and is associated with organ failure and high mortality rates.
• EA-230 is a new, β-hCG-derived immunomodulatory compound developed to modulate systemic inflammation and to protect organs.
What this study adds
• These first phase I studies using single, multiple and continuous dosage administration demonstrate that EA-230 has a non-proportional dose-exposure relationship, a large volume of distribution and a very high clearance rate.
• EA-230 is well tolerated by healthy volunteers without any safety concerns.
research personnel, who were not involved in data sampling, analysis or any other study-related activity.
| Subjects
Following written informed consent, healthy Caucasian adult males and females with a body mass index between 18 and 30 kg/m 3 were included. Before participation, health status was determined by medical history, physical examination, electrocardiogram (ECG) and routine laboratory blood tests. Female subjects were also required to have a negative pregnancy test result (urine hCG). Exclusion criteria included atopic constitution, presence and/or history of clinically significant allergies, use of any medication, significant blood loss and participation in any other clinical trial within 90 days prior to the study. The use of tobacco, recreational drugs, alcohol and/or caffeine 7 days prior to or during the study was not allowed. All subjects were fasted from the evening before (midnight) until 4 hours after the start of study drug administration, to exclude any dietary effects on the PK of the compound and for safety reasons.
| Study procedures
A schematic overview of the study procedures is presented in Figure 1 .
| Single dosage study
Thirty-two male subjects were assigned to one of four dosage groups:
1, 3, 10 and 30 mg/kg body weight. Each dosage group consisted of eight subjects, randomly assigned to receive either EA-230 or placebo (n = 6 active study drug, n = 2 placebo).
The study drug was administered as an i.v. bolus injection in 2 minutes for dosage groups 1 and 2 (1 and 3 mg/kg), and in 15 minutes for dosage groups 3 and 4 (15 and 30 mg/kg). Frequent blood samples for PK analyses were collected and subjects were monitored for 24 hours.
| Multiple dosage study
In this subsequent 3-day multiple dosage study, 24 healthy male volunteers were assigned to three escalating dosage groups: 10, 20 and 30 mg/kg body weight. Each dosage group consisted of eight subjects who were randomly assigned to receive either EA-230 (n = 6) or pla- For the multiple dosage study, study drug administration and safety assessments were performed thrice daily for 3 days, whereas PK assessments were performed following every first study drug administration of the day
| Continuous dosage study
Twenty-four subjects were assigned to three dosage groups: 15, 45 or 90 mg/kg/hour EA-230, for the duration of 2 hours. Each dosage group consisted of eight subjects (four males and four females) and within each dosage group subjects were randomly assigned to receive either EA-230 (n = 6) or placebo (n = 2), with equal numbers of males and females within active and placebo groups. The study drug was administered by 2-hour continuous i.v. infusion. Serial blood samples for PK analyses were collected and subjects were monitored until release from the research unit 8 hours after start of study drug administration. Subjects returned at Days 1, 2, 7 and 14 after study drug infusion for follow-up.
| Pharmacokinetic analyses
Blood samples for measurement of EA-230 concentrations were collected from the arm opposite to the one where EA-230 was administered. A schematic overview of the sampling time-points is provided in Briefly, a stable isotope-labelled internal standard of EA-230 (A*QGV; Caslo, Lyngby, Denmark) was added to 100 μL plasma sample, followed by the addition of 300 μL of acetonitrile. Five μL supernatant, obtained by passing the mixture through an OstroTM 96-well plate, was injected for chromatographic separation using a high performance liquid chromatography (HPLC) system. The retention time of EA-230 and its stable isotope-labelled internal standard was 2.2 min. A tandem mass spectrometer was used for the detection of the compounds, and quantification was based on the peak area ratios of EA-230 and its stable isotope labelled internal standard.
The detection range of the method was 0.5-100 ng/mL with low, medium and high quality control (QC) concentrations of 1.5, 10 and 75 ng/mL. Concentrations below the limit of quantification were not included in the PK analyses. Inter-run and intra-run precision coefficients of variation (CV) and accuracy relative error (RE) were determined for the low, intermediate and high concentration standards. Inter-run and intra-run CV were between 4.8-8.6% and 2.1-11.4%, respectively. RE were between −2.5-8.0% and −10.6-11.2%, respectively. EA-230 concentrations were shown to be stable at room temperature for 17 hours and at −80°C for up to 183 days.
The highest observed plasma concentration was defined as C max .
The area under the plasma concentration vs. time curve from t = 0 to the time of the last measured concentration (AUC 0-last ) was calculated using the linear-log trapezoidal rule, with extrapolation to infinity (using C last /β) to obtain the AUC from t = 0 to infinity (AUC 0-inf ). The log-linear period (log concentration vs. time) was defined by visual inspection of data points. The absolute value of the slope (β/2.303) was calculated by least squares linear regression analysis, where β is the first-order elimination rate constant. Elimination half-life (t 1/2 ) was calculated by the equation 0.693/β. Clearance (Cl) was calculated by dividing dose by AUC 0-inf and volume of distribution (Vd) by dividing Cl by β.
| Safety and tolerability assessments
On the study drug administration days of each study, frequent safety and tolerability assessments were performed until discharge and 
| Statistical analysis
Demographic data of each study are expressed as mean ± SD and compared using one-way analysis of variance (ANOVA). Adverse events are summarized by treatment group, preferred term, severity and relation to the study drug. PK parameters are presented according to treatment group using geometric mean and 95% confidence intervals (CI). Dose proportionality was assessed using unpaired Student's t-tests or one-way ANOVA followed by a Bonferroni post-hoc test on dose-normalized, log-transformed data. Dose accumulation in the multiple dosage study was assessed by repeated measures oneway ANOVA on log-transformed data. A p-value of <0.05 was considered statistically significant. Statistical calculations were performed using GraphPad Prism version 5.03 (GraphPad Software),
The PK analysis was performed with non-compartmental methods using WinNonLin/Phoenix version 6.3 (Pharsight Corporation, St.
Louis, MO, USA).
3 | RESULTS
| Subject disposition
All subjects were Caucasian and there were no differences in baseline characteristics between groups (Table 1 ). All subjects received study medication as intended and were deemed compliant to the study protocol. In the multiple dosage study, one participant was replaced after 1 day (three dosings) for personal reasons and the replacing participant withdrew after 2 days (six dosings) for work-related reasons.
The two subjects that did not complete the study were included in the safety analysis as they received study medication. However, because of incomplete PK data, these subjects could not be used for the PK analysis.
3.2 | Single dosage study
| Pharmacokinetics
Plasma EA-230 concentration-time profiles are presented in Figure 2 A and PK parameters are summarized in Table 2a . In the two lowest dosage groups (1 and 3 mg/kg), the maximum concentration observed was at the first time point (at t = 5 minutes, 3 minutes after administration had stopped). In the highest dosage groups (10 and 30 mg/kg), C max was reached before the end of infusion (at t = 10 minutes, 5 minutes before administration had stopped). A rapid decline in plasma concentration was observed; concentrations decreased below the limit of quantification for the four dosage groups at 15, 20, 45 and 120 minutes, respectively. With regard to this rapid decline in plasma concentrations, the elimination rate constant β and other β-dependent PK parameters (AUC 0-inf , t 1/2 , Vd, Cl) could not be determined for the lowest dosage groups. In the two highest dosage groups, a high volume of distribution (geometric means of 3 and 33 L/kg) and fast clearance rate (geometric means of 57 and 61 L/h/kg) were observed. Dose proportionality could not be assessed across all dosages as the duration of administration differed between the 1 and 3 mg/kg groups (2 minutes) and the 15 and 30 mg/kg groups (15 minutes). Nevertheless, the dosage increase from 1 to 3 mg/kg as well as that from 10 to 30 mg/kg resulted in a proportional increase in exposure parameters C max and AUC 0-last ( Figure 4A ).
| Safety and tolerability
Administration of a single dose of EA-230 was well tolerated by all subjects in every dosage group, and did not result in any safety concerns. No SAEs were reported. Six subjects (25%) treated with EA-230 and two placebo-treated subjects (25%) reported one or more AEs (Table 3a ). All AEs were mild and transient, and no dosedependent increase in number or intensity of AEs was observed. Most of the AEs were deemed unrelated to the study drug. Two subjects reported AEs which were considered possibly related to the study AUC 0-last 123%; Figure 4B ).
All dosages of EA-230, up to 90 mg/kg daily for 3 days, were well tolerated by all subjects and did not result in any safety concerns.
No SAEs were reported, and no subjects discontinued the study for safety reasons. Twelve subjects (61%) treated with EA-230 and three placebo-treated subjects (50%) reported one or more AEs, and no relevant dose-dependent increase in number or intensity of AEs was observed (Table 3b ). All AEs were mild and transient (with the exception of one moderately severe AE based on a venous injection site haemorrhage which was deemed unrelated to the study drug). Four AEs (17%) were considered possibly related to study drug treatment; two subjects (33%) in the lowest treatment group reported shortlasting postural dizziness and two subjects (33%) in the placebo group reported headaches.
Other non-related AEs are shown in Table 4b . All variations in laboratory parameters, vital signs and 12-lead ECG were considered not clinically significant.
| Continuous dosage study
| Pharmacokinetics
In the lowest dosage group (15 mg/kg/h), one subject was excluded from all PK analyses because of an abnormal pattern of plasma concentrations of EA-230, with high concentrations at baseline, probably due to an interchange of tubes.
Plasma EA-230 concentration-time profiles are presented in Figure 2C and PK parameters are summarized in Table 2c . In all three dosage groups, stable plasma concentrations were attained 15 minutes Data expressed as geometric means and 95% CI (No 95% CI for data with n = 2). t 1/2 , elimination half-life; C max , highest observed plasma concentration; AUC 0-last , the area under the plasma versus concentration time curve from t = 0 to the time of the last measured concentration; AUC 0-inf , the area under the plasma versus concentration time curve from t = 0 to infinity extrapolated; Cl, plasma clearance; Vd, volume of distribution.
| Safety and tolerability
Continuous infusion of EA-230 was well tolerated by all subjects in every dosage group, and did not result in any safety concerns and/or discontinuation of study drug administration. No SAEs were reported.
Eight subjects (44%) treated with EA-230 and one placebo-treated subject (17%) reported one or more AEs (Table 3c ). All AEs were mild and transient, and considered unlikely to be or not related to the study drug. Short-lasting dizziness was observed in two subjects in the highest dosage group (33%), and ceased after eating in one subject.
Flu-like symptoms were reported by two subjects in the intermediate (17%) and highest dosage group (17%), both starting at least 24 hours System organ class and preferred term n (%) e n (%) e n (%) e n (%) e n (%) e
Number of subjects with at least one AE 1 (16. All three studies showed a large volume of distribution and a very rapid clearance, resulting in a short half-life, confirming previous animal data (see Supplemental data file) . However, with regard to the short half-life, we were only able to provide an estimate of these variables, representing a limitation of this study. In the bolus infusion studies, low concentrations approaching the limit of detection were observed already early after administration, therefore only limited time points were available and concentrations close to the limit of An excellent safety and tolerability profile were observed for EA-230 as no SAEs were reported, AEs were mild and transient, did not result in discontinuation of study drug administration and the vast majority of the AEs observed were deemed unlikely to be or not related to the study drug. Six AEs were considered possibly related to the study drug, but the evidence for the relationship between these AEs and study drug administration is unconvincing for several reasons.
First, 50% of these AEs were observed in subjects treated with placebo. Second, the other AEs were all observed in the lowest dosage groups of each particular study. Noteworthy, there were no possible related AEs reported in the study where continuous infusion of EA-230 was employed, which resulted in the highest plasma concentrations and the longest exposure to the drug. Nevertheless, in this continuous infusion study, only one AE occurred in the placebo group compared with eight AEs in the treatment groups, with more AEs occurring in the higher dosage groups, indicating that a possible relation to the study drug cannot be entirely excluded. Upon review of the specific AEs, complaints of dizziness were reported in all studies.
In the bolus studies, all possible related AEs in subjects with active treatment were complaints of (postural) dizziness. Also, in the continuous infusion study, although considered unlikely or not related, dizziness was observed in two subjects in the highest dosage groups.
Although this pattern of complaints of dizziness might indicate a relation with administration of EA-230, similar complaints could well be explained by the long period of fasting by these subjects in all three studies. Furthermore, no changes in vital parameters between groups (A) (B) (C) FIGURE 4 Dose proportionality of dose-normalized, log-transformed exposure parameters C max and AUC 0-last . A, Single dosage study, dose proportionality could not be assessed across all dosages as the administration duration differed between the 1 and 3 mg/kg groups (2 minutes) and the 15 and 30 mg/kg groups (15 minutes). B, Multiple dosage study, as no dose accumulation was observed in this study (see Figure 3 ), the average values over the 3 days for each subject were used. C, Continuous dosage study. A p-value of <0.05 indicates non-proportionality. Linear regression lines are shown, dotted lines indicate the 95% confidence interval were present in all studies (data not shown), nor did preclinical data indicate any effect of EA-230 on blood pressure or heart rate (unpublished data). Therefore, it appears unlikely that the reported dizziness would be related to haemodynamic effects. Taking into account all available data on safety and tolerability, no relevant safety issues for the i.v. administration of EA-230 to humans within the dosage range tested were observed. Although sample sizes were relatively small, and therefore side-effects that are rare might still go unnoticed, the proposed sample sizes were selected in line with generally used sample sizes for first-in-human phase I studies. The total of 80 volunteers in the three phase I studies with EA-230 would generally be regarded as sufficient. Based on these results, a phase IIa study in volunteers exposed to endotoxin has been conducted to investigate the immunomodulating properties of EA-230 (described elsewhere in this issue 33 ) and a clinical trial in cardiac surgery patients has been initiated. 34 In conclusion, these dose-escalating phase I studies with different administration strategies, describe a PK profile of EA-230 with a large volume of distribution and a short half-life, and demonstrate that i.v.
administration is well tolerated without any safety issues emerging.
These results enable further clinical development to assess safety, tolerability and immune modulating efficacy in humans during systemic inflammation.
